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III. Abstract
Idiopathic gastroparesis is a chronic symptomatic motility disorder of the stomach of
unknown cause characterized by delayed gastric emptying in the absence of mechanical
obstruction, with the majority of gastroparesis cases being classified as idiopathic. 1-3 Idiopathic
gastroparesis continues to be a challenging diagnosis to manage and difficulty remains in treating
associated symptoms that result in decreased quality of life. Current non-invasive
recommendations for the treatment of idiopathic gastroparesis are lifestyle modifications,
including dietary adjustments to follow a gastroparesis diet, and pharmacotherapy prescribed for
symptomatic relief. Metoclopramide is currently the only medication approved by the Food and
Drug Administration (FDA) in the United States specifically for the indication of treating
gastroparesis. Other medications are prescribed off-label for the indication of idiopathic
gastroparesis or are prescribed to target specific symptoms. Response to treatment is both
individualized and unpredictab e, a d

edica i

ide-effects may necessitate discontinuance.

In the treatment of adults with idiopathic gastroparesis, it has been concluded that lifestyle
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modifications, pharmacotherapy, or both may improve, eliminate or fail to improve the
symptoms of nausea, vomiting, early satiety, and poor appetite. Ultimately, risks and benefits of
each option need to be discussed and shared decision-making needs to occur to establish a
treatment regimen and management plan for patients with idiopathic gastroparesis.
IV. Introduction
Idiopathic gastroparesis continues to be a challenging diagnosis to manage and difficulty
remains in treating associated symptoms, which result in morbidity, and complications, leading
to both morbidity and mortality. Gastroparesis is a chronic symptomatic motility disorder of the
stomach characterized by delayed gastric emptying in the absence of mechanical obstruction,
with the majority of gastroparesis cases being classified as idiopathic.1-3 Common causes of
gastroparesis are diabetes, prior gastric surgery, and endocrine, neurologic, or hematologic
disorders.4 Medications, such as opioid analgesics and anticholinergic medications, can also
cause gastroparesis by delaying gastric emptying.4 When these common causes have been ruledout and the cause remains unknown, the disorder is classified as idiopathic gastroparesis. 4
In the United States, at least 4 million adults have the diagnosis of gastroparesis. 5 The
incidence of gastroparesis is 6.3 per 100,000 persons per year.5 Most patients with gastroparesis
are females (often by a 3:1 margin) with age-adjusted prevalence of 37.8 per 100,000 persons for
females and 9.6 per 100,000 persons for males.4-6 Parkman et al. note that most gastroparesis
studies enroll primarily white female patients,4 and idiopathic gastroparesis is most commonly
diagnosed in white patients.4 Females also have slower gastric emptying than males, which is
believed to be due to estrogen and progesterone (female sex hormones).4,6 Compared to males,
females reported more severe symptoms of stomach fullness, early satiety, postprandial fullness,
bloating, and upper abdominal pain.4 Females also had a stomach that was visibly larger.4 Over
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time, females reported better improvement in their symptoms than males.4 On the other hand,
more males than females were hospitalized during the year prior to the study.4
The constellation of symptoms most commonly associated with idiopathic gastroparesis
are nausea (>90% of patients), vomiting (84% of patients), early satiety (feeling full after
consuming only a small amount of food) (60% of patients), abdominal distension, bloating,
abdominal pain, and postprandial fullness (feeling excessively full after meals). 2-7 Gastroparesis
reported symptoms are listed in Table 1.5 Nausea, vomiting, early satiety, and postprandial
fullness are best correlated with a delay in gastric emptying, whereas bloating and abdominal
pain may be related to sensory alterations that might be present.6 Some patients experience
constant persistent symptoms, while others may experience completely symptom-free periods of
time alternating with intermittent symptomatic flares.6 The symptoms and complications
associated with idiopathic gastroparesis can result in permanent disability, vulnerability to
thrombosis, and greater mortality.2
Idiopathic gastroparesis not only results in both morbidity and mortality, but also causes
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and Drug Administration) approved medication treatment options in the United States to manage
the complex motility disorder. The side-effects associated with various medications also limit
their use for long-term treatment. The varying symptoms and degree of symptom severity make
formulating a treatment plan difficult, including determining whether lifestyle and dietary
changes, medication, or both are necessary for management. In utilizing the least invasive
treatment options first, the research question is: in adults with idiopathic gastroparesis, how does
lifestyle modifications, including changing diet and eating habits, compared to pharmacotherapy
(medications) affect the symptoms of nausea, vomiting, early satiety, and poor appetite? Due to
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the variation in both symptoms and severity, more than likely the treatment regimen (lifestyle
modifications and/or pharmacotherapy) will need to be adjusted on a case-by-case basis and will
not be uniform across cases of patients with a diagnosis of idiopathic gastroparesis. This paper
will outline how to establish the diagnosis of idiopathic gastroparesis, recommended eating
habits and dietary modifications, and pharmacotherapy utilized to treat idiopathic gastroparesis.
V. Background: Literature Review
Establishing the Diagnosis of Idiopathic Gastroparesis
The gold standard for evaluating gastric emptying to establish the diagnosis of
gastroparesis is scintigraphic gastric emptying of a solid meal, most reliably during a 4-hour
study, during which the patient consumes a low-fat, egg white meal (scrambled eggs) labeled
with a radionuclide (e.g., 99m technetium) that binds to protein in the eggs.7-9 Patients must stop
any medications that could potentially affect gastrointestinal motility 72 hours prior to the study,
fast overnight (nothing to eat after midnight, which is an 8-hour fast), and report to the Nuclear
Medicine Department where the test is scheduled and completed.8-9 The Nuclear Medicine
Department follows a multicenter protocol (endorsed by the Society of Nuclear Medicine and
Molecular Imaging [SNMMI] and American Neurogastroenterology and Motility Society
[ANMS]) to ensure standardized information about delayed gastric emptying is utilized across
testing sites.7,9 Scintigraphic images are obtained over a period of 4 hours (at 0, 1, 2, and 4 hours
after meal ingestion), and the rate of gastric emptying is determined by the amount of food
remaining in the stomach in each image.7-9 Results demonstrating delayed gastric emptying of
solids (solid food retention in the stomach) are scintigraphy of greater than 60% of food retained
at 2 hours and/or greater than 10% at 4 hours.7,9 Greater than 10% gastric retention after 4 hours
is considered the gold standard for diagnosing gastroparesis.5 Though there are no clearly agreed
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upon standards for classifying the severity of delay in gastric emptying,5 a couple studies noted
that the delayed gastric emptying can then be graded according to the amount of gastric retention
a 4h

:

i d ( 20% e e i ),

de a e (>20

35%) a d e e e (>35%).7,9 The

Gastroparesis Cardinal Symptom Index (GCSI) is a questionnaire utilized to assess symptoms
and severity, which scores symptoms of nausea and vomiting, postprandial fullness and early
satiety, and bloating over the preceding two weeks.6 Esophagogastroduodenoscopy (also known
as an upper endoscopy or EGD) is utilized to view the esophagus, stomach and duodenum to
rule-out obstruction as a cause of symptoms.
General Measures of Management
The management and treatment of idiopathic gastroparesis can be complicated and
frustrating to both patients and healthcare providers due to the complexity of symptoms,
unpredictable response to treatment, limited availability of medications, and side-effects
associated with medications utilized for treatment. Symptoms of idiopathic gastroparesis can
lead to food aversion and inadequate oral intake with subsequent dehydration, malnutrition,
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life and their ability to sustain their health and engage in social interactions.2,4,7 Long-term
gastroparesis has also been associated with esophagitis (inflammation of the esophagus),
Mallory-Weiss tears (tears in the tissue of the lower esophagus), and severe peptic ulcer disease
(stomach and/or duodenal ulcers).3 Idiopathic gastroparesis cannot be cured; rather, the goal of
treatment is to control associated symptoms.10 Risks and benefits associated with specific
treatment options and deciding whether to continue treatment need to be consistently analyzed
and actively discussed. Patients diagnosed with gastroparesis are willing to take exceedingly
high risks with medications in order to improve their symptoms, often trading longevity for

f
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symptom relief, choosing quality of life over quantity of years.5 Establishing rapport and
participating in shared decision-making with patients with idiopathic gastroparesis during
consistent follow-

ffice i i c ea e a c cia f

da i

i e a a i g he a ie

and quality of life, discussing treatment goals, and ultimately formulating a treatment regimen.
The management of idiopathic gastroparesis depends on the severity of the gastric
emptying and symptoms associated with the disorder. Most patients present with dehydration
and electrolyte disturbances, complications of their symptoms.3 Therefore, the goals of initial
treatment include fluid resuscitation and maintaining adequate hydration; correcting the
electrolyte abnormalities and nutritional deficiencies; management of any underlying
comorbidities; and improving, suppressing, or eliminating symptoms.3,6 Furthermore, a thorough
history and physical examination should be performed to identify and treat comorbid conditions
and to identify and discontinue any medications that may be delaying gastric emptying or
ca i g he a ie

.3 Medications known to impair gastric motility include certain

anticholinergic agents, Glucagon-like peptide 1 (GLP-1) analogs, and opiate narcotics.11
Lifestyle modifications, including dietary adjustments, and pharmacotherapy (to control
symptoms) are recommended initially for the treatment of patients with mild idiopathic
gastroparesis.3 The most commonly prescribed medications are metoclopramide, domperidone
and erythromycin.5 Whereas more severe symptoms, including marked dehydration, intractable
nausea with vomiting, and malnutrition, may require hospitalization, medications, and potentially
more invasive interventions for treatment and subsequent management of he a ie

idi

a hic

gastroparesis.3 Figure 1 presents a stepwise approach to gastroparesis.8 Figure 2 offers suggested
therapeutic options for gastroparesis.11
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Severely delayed gastric emptying has been associated with an increased risk of
hospitalization and an increase in visits to the emergency department (ED).5 Since 2005,
hospitalizations and the associated costs have increased significantly for patients with
gastroparesis.5 Furthermore, these patients experience the longest length of hospitalization and
the second highest total healthcare cost among upper gastrointestinal conditions,5 demonstrating
the need for active management of symptoms in the outpatient setting to potentially decrease or
prevent ED visits and subsequent admissions. Lastly, the use of opioids in patients with
idiopathic gastroparesis further complicates management and treatment, which will be discussed
in the pharmacotherapy section. To reduce ED visits, hospitalizations, and associated healthcare
costs, patients with severely delayed gastric emptying and severe symptoms associated with
idiopathic gastroparesis need to be quickly identified and a treatment plan established and
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setting.5
Lifestyle Modifications
Lifestyle modifications, specifically dietary adjustments, are generally the initial
treatment when managing patients with idiopathic gastroparesis. Dietary goals include improving
oral intake, maintaining hydration and nutrition, improving or eliminating symptoms, and
managing any complications that arise. Patients with more severe delays in gastric emptying are
less likely to meet their daily total energy requirement (TER) through oral intake.7 Adjustments
are recommended for both meal content and the frequency of meal consumption for patients with
idiopathic gastroparesis.3 Since larger volumes slow gastric emptying and worsen early satiety,
small frequent meals (4 to 6 per day) are suggested to maintain caloric intake, prevent nutritional
deficiencies, and minimize symptoms of postprandial fullness, nausea, and vomiting. 7-8,10
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If energy and nutrition supplementation is needed, high protein caloric liquids are
recommended, since liquids more readily empty the stomach and are better tolerated than solids
in patients with idiopathic gastroparesis.7-8 Twenty percent of patients with gastroparesis report
utilizing supplemental nutrition to meet their daily TER.12 Since patients with idiopathic
gastroparesis generally have preserved gastric emptying of liquids, liquid-based meals are
recommended for patients who cannot tolerate solid food.3 Patients should be encouraged to
drink at least one to one-and-a-half liters of fluid per day to maintain hydration.8 Fluids should
also be drunk throughout the course of a meal, and patients should sit or walk for one to two
hours after meals.10 Carbonated beverages should be avoided as they exacerbate symptoms such
as bloating, gastric distension, and gastroesophageal reflux.8 Poor tolerance to a liquid diet is
usually indicative of a future poor outcome.10
The consumption of fats or lipids is known to slow or delay gastric emptying, while fiber
can increase bloating and may cause early satiety.7 Fats and non-digestible fibers should be
avoided, whereas foods low in fat and fiber are recommended to compensate for the impairment
of gastric emptying.3,7,11 A low fiber diet also decreases the risk of bezoar formation, a solid
mass of indigestible material, usually retained food debris, that can form in the stomach and
potentially cause obstruction.8 A bezoars needs to be mechanically disrupted endoscopically or
potentially enzymatically digested with an agent such as papain, cellulose, and N-acetylcysteine.8
Foods worsening symptoms in patients with idiopathic gastroparesis are generally fatty, acidic,
spicy, or roughage-based, including orange juice, fried chicken, cabbage, oranges, sausage,
pizza, peppers, onions, tomato juice, lettuce, coffee, salsa, broccoli, bacon and roast beef.13
Saltine crackers, jello, and graham crackers were shown to moderately improve symptoms. 13
Additional foods tolerated by patients (foods that did not provoke symptoms) are generally

Idiopathic Gastroparesis: Lifestyle Modifications Versus Pharmacotherapy 9
bland, sweet, salty or starchy, including ginger ale, gluten-free foods, tea, sweet potatoes,
pretzels, white fish, clear soup, salmon, potatoes, white rice, popsicles, and applesauce. 13 Table 2
details a nutritional analysis of aggravating and tolerated foods.13 Table 3 specifies food qualities
of aggravating and tolerated foods.13
Nutritional deficiencies, including calories, carbohydrates, protein, vitamins, and
minerals, are common in patients with idiopathic gastroparesis.2,6-7 Because symptoms can lead
to food aversion and poor oral intake, malnutrition is a complication associated with idiopathic
gastroparesis.2,6-7 Patients with idiopathic gastroparesis are more likely to consume diets
deficient in vitamins A, B6, C, K; iron; potassium; and zinc, but only about one-third of patients
report taking a daily multivitamin supplement.6-7 Screening blood tests that can be ordered to
evaluate for malnutrition are a complete blood count (CBC) with differential, coagulation factors
(international normalized ratio [INR]), and a complete metabolic panel (which includes both
renal and liver profiles).8 Kedar et al. further explored Vitamin D deficiencies in patients with
gastroparesis.2 Associations were identified between micronutrient deficiencies and impaired
gastric motility, specifically indicating an association between low 25-Hydroxy (25-OH)
Vitamin D levels and impaired motility in patients with gastroparesis.2 Based on this association,
baseline serum 25-OH Vitamin D levels are recommended to be drawn at the initial clinic visit
for patients with gastroparesis and if low, supplementation prescribed to maintain healthy levels
of serum 25-OH Vitamin D.2 Further mineral and vitamin screening may also be ordered if
warranted, including vitamin B12, folic acid, serum iron, total iron binding capacity (TIBC),
percentage of iron saturation, and zinc levels.8
Patients with deficient diets generally report more severe symptoms associated with
idiopathic gastroparesis. Patients who reported energy-deficient diets experienced more severe
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symptoms, specifically bloating and constipation.6-7 Patients consuming caloric deficient diets
(defined as less than 60% of estimated daily TER) reported significantly higher symptom scores
for stomach fullness, excessive fullness after a meal, bloating and constipation. 7,14 In a study of
gastroparesis patients (both idiopathic and diabetic etiologies were included), 64% of patients
reported caloric-deficient diets, only 2% of patients followed a diet recommended for patients
with gastroparesis, and only 32% had a nutritional consultation after the onset of gastroparesis.7
Overall, due to the occurrence of nutritional deficiencies, patients with idiopathic gastroparesis
may require additional vitamin and mineral supplementation.
As noted, a gastroparesis diet is rarely followed, and a nutritional consultation is often not
completed. Proposed reasons for lack of adherence to following a gastroparesis diet are the lack
of consensus regarding an optimal gastroparesis diet, inability to achieve the requirements of the
gastroparesis diet as recommended (diet composition and/or frequency), unawareness of the
existence of a gastroparesis diet, lack of education regarding dietary recommendations for
gastroparesis, or patients choose not to follow the recommended diet.7 Other obstacles may
include the inability to
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frequent breaks to adhere to consuming small frequent meals advised for patients with idiopathic
gastroparesis, or workplaces prohibiting patients from keeping food near their work area.
Nutritional consultations are helpful for not only education regarding a gastroparesis diet and
meal preparation but also assistance in creating individualized, achievable diet plans for patients
with idiopathic gastroparesis. Patients with longer duration of symptoms, those who were more
ill (exhibiting increased severity of symptoms), and those who had more hospitalizations were
more likely to have participated in nutritional consultations.6-7 Not noted was who performed the
nutritional consultations (a healthcare provider versus a registered dietitian). Also not noted was
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whether the nutritional consultations occurred while admitted as an inpatient in a hospital setting
or in an outpatient clinic setting. Nutritional consultation increased the chance ha
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intake met daily TER.6
Challenges exist preventing scheduling and completion of nutritional consultations.
Patients may have difficulty taking time off work to attend appointments with a registered
dietitian. An outpatient dietitian consultation appointment is not always covered b

he a ie

medical insurance, which results in the entire bill needing to be paid directly by the patient.
Unfortunately, the cost of an appointment with a registered dietitian can deter patients from
completing these nutrition consultations in an outpatient setting. Though a nutrition consult may
be helpful for education regarding a gastroparesis diet, meal planning, and addressing nutritional
deficiencies, it may not be financially feasible for all patients.
Pharmacotherapy
The goal of pharmacotherapy (treatment utilizing medication) is to alleviate symptoms
and promote gastric emptying. However, no single medication is effective in managing the delay
in gastric emptying and associated symptoms of gastroparesis, making treatment complicated
and challenging for healthcare providers.3 Table 4 displays pharmacotherapy treatments tried for
gastroparesis symptoms in a study by Navas et al.5 A combination of multiple medications,
including prokinetics, antiemetics, and neuromodulators, may be required to relieve symptoms in
severe cases.14 The use of multiple medications metabolized by cytochrome P-450 enzymes in
the liver may lead to drug-drug interactions, further complicating the combined use of these
pharmacological classes.14 Table 5 lists novel drugs and whether the medication exhibits
antiemetic effects and/or prokinetic effects.19 Table 6 provides the mechanisms of action of novel
drugs utilized in the treatment of idiopathic gastroparesis.19 One retrospective study notes that
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neither the type of gastroparesis (determined by underlying cause) nor extent of delay in gastric
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tricyclic antidepressants, analgesic and invasive interventions.15 The same study notes a
correlation between the response to treatment and symptoms of stomach distention, bloating, and
the Gastroparesis Cardinal Symptom Index.15
Nausea severity decreases the quality of life for patients with idiopathic gastroparesis, so
the disabling symptoms of nausea and vomiting need to be specifically evaluated and treated. 9-10
A significant association was found between increased antiemetic use and increased ED visits
and hospitalizations.5 Navas et al. report that more than half of the patients in their study had
been prescribed an antiemetic medication for symptomatic treatment,5 and most patients had
tried more than one antiemtetic.5 Antiemetics, including phenothiazines, antihistamines, and 5hydroxytryptamine 3 (5-HT3) receptor antagonists, are prescribed to improve or suppress
symptoms of nausea and vomiting in patients with idiopathic gastroparesis.6,11 There is not a
single antiemetic drug or class of drugs that has emerged as the best option for treating nausea
and vomiting in patients with idiopathic gastroparesis.8,11 Phenothiazines, which includes
prochlorperazine, are dopamine and cholinergic receptor antagonists.10 This class of medication
acts on the chemoreceptor trigger zone in the brainstem.10 Side effects of phenothiazines include
sedation, extrapyramidal effects (movement disorders), tardive dyskinesia (involuntary
movements of the face and jaw), drowsiness, dry mouth, constipation, and skin rashes. 10 5-HT3
antagonists, such as granisetron and ondansetron, can be prescribed for patients with idiopathic
gastroparesis when nausea and vomiting are the dominating symptoms and cardiac risks are
increased by prokinetics.14 Aprepitant is another antiemetic, a neurokinin-1 receptor antagonist,
that increases gastric accommodation, improves some digestive symptoms, and has been shown
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to be effective in case reports of severe gastroparesis.11 However, aprepitant does not affect
gastric emptying.14 Tradipitant is a new neurokinin antagonist that has shown improvement in
nausea in patients with idiopathic gastroparesis with moderate-to-severe nausea.14 Ultimately, the
choice of antiemetic used to treat the patient with idiopathic gastroparesis should be based on the
patie
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of administration, as some antiemetics are available transdermally, such as transdermal
granisetron, or rectally, reducing the variability in drug absorption in patients with frequent
vomiting.8,11,14 Transdermal granisetron delivers a sustained controlled dose over the course of
24 hours, reduces nausea and vomiting in patients with gastroparesis, and has a decreased risk of
electric dysrhythmias when compared to oral granisetron.16,19
Prokinetic medications stimulate gastric motor activity through an increase in antral
contractility, correct gastric dysrhythmias, and improve coordination between the antrum and
duodenum leading to enhanced propulsive motility, thereby promoting the movement of contents
from the stomach, causing caudal displacement of luminal contents.3,6,10 These agents may
predominantly improve symptoms of nausea, vomiting and bloating as they do not seem to
relieve abdominal pain nor early satiety associated with gastroparesis.10 Though prokinetic
agents may improve the rate of gastric emptying, the medication may not improve symptoms
associated with idiopathic gastroparesis.5 Prokinetic agents are noted to have modest efficacy
and should be adjusted or discontinued based on symptom response and side-effects.3 One study
demonstrated that utilizing prokinetic medications to treat patients with gastroparesis did not
decrease their length of hospitalization nor their rates of 30-day readmission.17
Dopamine receptor antagonists utilized in the treatment of idiopathic gastroparesis
include metoclopramide and domperidone. Both metoclopramide and domperidone accelerate
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gastric emptying and have independent anti-nausea effects.3 These two medications will be
further discussed. Levosulpiride, an antipsychotic agent, is a dopamine receptor D 2-antagonist
that accelerates gastric emptying by exerting both antidopaminergic and 5-hydroxytyramine 4 (5HT4) agonistic properties and is expected to reverse dopaminergic inhibition on gastric
contraction, but it is not yet approved by the FDA.10,14 Levosulpiride improved symptoms in
patients with idiopathic gastroparesis without correlation with the acceleration of gastric
emptying.14
Metoclopramide is the only pharmacotherapy currently approved by the United States
FDA for the treatment of gastroparesis.1,3,5,8 It is a benzamide derivative that primarily acts as a
peripheral dopamine D2-receptor antagonist but stimulates 5-HT4 receptors, which augments the
release of acetylcholine in the myenteric plexus within the gut wall, causing increased lower
esophageal sphincter tone, antral contractility, fundic tone, pyloric function, antroduodenal tone
and coordination, and jejunal peristalsis.3,8 Therefore, this medication accelerates gastric
emptying. Metoclopramide directly acts on both the chemoreceptor trigger zone and intracerebral
vomiting center, which causes central antiemetic effects and symptom improvement. 8 Navas et
al. report that just under half of patients in their study had been prescribed metoclopramide.5 Of
these patients, 43% reported experiencing symptomatic improvement while taking
metoclopramide.5 35% of patients reported experiencing adverse effects directly related to taking
this medication.5 Yet, the FDA estimates that adverse effects occur in only about 10% of patients
taking metoclopramide.5 Metoclopramide crosses the blood-brain barrier and can result in
neurological adverse-effects and extrapyramidal movement disorders, including Parkinsonism,
tardive dyskinesia, akathisia, and acute dystonic reactions (facial spasm, oculogyric crisis,
trismus and torticollis), resulting in the need to discontinue the medication and ultimately
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limiting its use.1,3,10 Due to the extrapyramidal side effects, the FDA placed a black-box warning
on metoclopramide in 2009, which consequently caused the number of patients taking the
medication to decline by more than 50%.8,18 Other reported side-effects include somnolence,
drowsiness, fatigue, lassitude, anxiety, restlessness, irritability, depression, reduced mental
acuity, and hyperprolactinemia.3,10 Metoclopramide is also available as a nasal spray, which is
helpful for patients unable to tolerate oral medications.19 Side-effects associated with intranasal
metoclopramide are dysgeusia, headache and fatigue.19 Despite the chronicity of idiopathic
gastroparesis, the FDA recommends the use of metoclopramide for no longer than 12 weeks,
unless patients experience a therapeutic benefit that outweighs the potential risks of the
medication.8,14
Domperidone is a dopamine receptor antagonist that chiefly acts on the peripheral
dopamine D2-receptors, exhibiting both prokinetic and antiemetic effects.3,8,14 Its mechanism of
action is similar to metoclopramide, as it accelerates gastric emptying by inhibiting fundic
relaxation and promotes antroduodenal coordination. 3 However, domperidone does not cross the
blood-brain barrier and therefore causes fewer central nervous system side effects than
metoclopramide.8 One study notes that gastroparesis patients reported better tolerance and
greater symptom improvement while taking domperidone than metoclopramide.5 Although,
domperidone is more challenging to prescribe due to its lack of FDA approval in the United
States.5 Navas et al. report that domperidone was prescribed to over 25% of patients in their
study.5 Of these patients, 46% reported symptom improvement while taking domperidone, and
9% reported adverse effects associated with the medication.5 Patients with gastroparesis taking
domperidone experience improvement in postprandial fullness, nausea, vomiting and stomach
fullness.20 Furthermore, domperidone improved the observed diminished quality of life in
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patients with gastroparesis in three separate studies.11 Side-effects of domperidone include dry
mouth, headaches, hyperprolactinemia symptoms, may prolong QTc interval, and though rare,
can cause cardiac arrhythmias and increase the risk of sudden cardiac death. 8,11 Due to potential
cardiac adverse effects, a baseline electrocardiogram (ECG) is recommended prior to initiation
of therapy, and follow-up ECGs while on therapy should also be considered.8 Though
domperidone is widely used in many countries and available over the counter in some countries,
it is not currently approved by the FDA in the United States for use in patients with idiopathic
gastroparesis and is only approved as a special FDA investigational drug program in the United
States for patients who have failed standard therapy.1,3,8,14,19 According to one study, healthcare
providers may write or print a prescription for domperidone and provide it to the patient for the
patient to legally purchase domperidone through an international pharmacy.11 Stein et al. caution
this, however, due to the potential cardiac adverse events associated with domperidone and
further state that there has also been an increase in requests for the medication to be withdrawn
from the market completely.11 Risks and benefits need to be discussed with patients
contemplating the initiation of domperidone for treatment of their symptoms associated with
idiopathic gastroparesis.
Bethanechol is a smooth muscle muscarinic agonist that is prescribed in addition to other
prokinetic medications in patients whose symptoms have not improved with commonly
prescribed prokinetic and antiemetic drugs.10 Adverse effects of bethanechol include abdominal
cramps, skin flushing, diaphoresis, lacrimation, salivation, nausea, vomiting, bronchialconstriction, urinary urgency, and miosis.10 Efficacy of bethanechol in patients with idiopathic
gastroparesis was not noted.
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Motilin receptor agonists include erythromycin, mitemcinal, antimotin, and ghrelin.3
Motilin is an endogenous hormone that stimulates gastric emptying through cholinergic activity
in the antrum.8,19 Previous studies with motilin receptor agonists demonstrated that they were
ineffective in treating symptoms of gastroparesis, and tachyphylaxis (development of tolerance
to the medication) was a common side effect.19
Erythromycin is a macrolide antibiotic that acts as a motilin receptor agonist and is a
potent prokinetic agent, improving gastric emptying. 1,3,8,11 Erythromycin does cause side-effects
of an antibiotic agent, including skin rashes, nausea, cramping and abdominal pain.3,10 When
used in the treatment of idiopathic gastroparesis, a lower dosage is prescribed since erythromycin
exhibits its gastric emptying effects even in lower doses.3 Similar to other agents, erythromycin
may be associated with prolongation of the QTc interval and increased risk of sudden cardiac
arrest, thus careful ECG monitoring is necessary.8,10,11 Tachyphylaxis continues to be a major
problem in the utilization of erythromycin, limiting its use long-term for the treatment of
idiopathic gastroparesis.1,3,8
Azithromycin, a macrolide antibiotic similar to erythromycin, is also a motilin receptor
agonist that improves antroduodenal contraction after intravenous (IV) administration.10
Azithromycin has a lower potential to cause cardiac arrhythmias than erythromycin and fewer
adverse effects since it is not metabolized by the cytochrome P-450 metabolic pathway in the
liver.10 However, IV administration of azithromycin did not show improvement in gastric
emptying or patient symptoms.10
Mitemcinal may have a role in the treatment of symptoms experienced by patients with
idiopathic gastroparesis. Mitemcinal (GM-611) is a macrolide-derived motilin receptor agonist
with prokinetic properties.3,10,19 Mitemcinal improved upper gastrointestinal symptoms when
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prescribed to patients with type 1 and 2 diabetes at 10 milligrams twice daily,3 but no study
results were provided regarding its effects on symptoms in patients with idiopathic
gastroparesis.3 Another study with mitemcinal failed to demonstrate an increase in gastric
emptying when compared to placebo.19
Antimotin is a motilin receptor agonist.3 IV administration of Antimotin in healthy
individuals accelerated gastric emptying of liquids and solids without significant effects on colon
transit.3 However, no studies have demonstrated this effect in patients with idiopathic
gastroparesis.3
Ghrelin is an endogenous peptide (hormone) derived from the gastric mucosa.3,19 It is
similar in structure to motilin, exhibiting prokinetic effects mediated by vagal signaling, which
seems to play an important role in the regulation of both appetite and body weight.3,19 In animals,
ghrelin has shown prokinetic (motility-stimulating) properties.3 Ghrelin accelerated gastric
emptying after a test meal in diabetic patients with slow gastric emptying in one study and
improved gastric emptying in patients with idiopathic gastroparesis in another study.3 TZP-101 is
a cyclic ghrelin analog that, when administered intravenously, accelerated gastric emptying and
improved symptom severity when compared with placebo.11 Its oral counterpart TZP-102 failed
to demonstrate a benefit during the follow-up 12-week phase IIb trial.11
Two medications studied in clinical trials for the treatment of gastroparesis are
Relamorelin and Camicinal. Relamorelin is a medication that has shown potential in the
treatment of gastroparesis symptoms. A clinical trial of subcutaneous injection of Relamorelin
(RM-131), a small molecule synthetic pentapeptide ghrelin agonist, accelerated gastric emptying
of solids via stimulation of gastric contractions in patients with diabetic gastroparesis and
improved subjective vomiting severity and symptoms of nausea, fullness, bloating and
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pain.11,14,19 Two additional trials also demonstrated that Relamorelin accelerated gastric
emptying with mixed results regarding symptomatic improvement in patients with
gastroparesis.14 The most common adverse effects reported for Relamorelin are dizziness,
headache, and hyperglycemia.19 In different clinical trial, Camicinal (GSK962040), a small
molecule selective motilin receptor agonist, improved gastric emptying and symptoms in patients
with diabetic gastroparesis and had a reduced incidence of tachyphylaxis.11,19 The effects of
Relamorelin and Camicinal in patients with idiopathic gastroparesis was not specifically noted.
5-HT4 receptors are located throughout the gastrointestinal tract and when activated,
release acetylcholine at the myenteric plexus.19 This leads to increased muscular contractions and
accelerated transit throughout the gastrointestinal tract.19 Cisapride and tegaserod are both nonselective 5-HT4 agonists.3,8,19 Unfortunately, these two 5-HT4 agonists are associated with
cardiac dysrhythmias.8 Cisapride was formerly the treatment of choice for gastroparesis and
gastroparesis-related symptoms, as it demonstrated efficacy in improving gastric emptying.3,11
Cisapride was withdrawn from the market due to significant cardiac side effects, including
ventricular cardiac arrhythmias and sudden cardiac death.3,11 It is now only available under
compassionate care programs.3 Tegaserod is another 5-HT4 agonist that has shown conflicting
results in its effects on gastric emptying in healthy individuals but was possibly associated with
ischemic cardiovascular events.3,19 Tegaserod was also removed from the market due to adverse
cardiac effects.19 Revexepride is a highly specific potent 5-HT4 receptor agonist that failed to
show differences in gastric emptying or symptomatic improvement in clinical trials.19 Velusetrag
is a selective 5-HT4 receptor agonist that has a 500-fold selectivity and affinity to the 5-HT4
receptor with no effect on the 5-HT cardiac receptors and was considered a promising prokinetic
as it indeed provided symptom relief and accelerated gastric emptying.8,14,19 RQ-00000010, a
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well-tolerated highly selective 5-HT4 receptor agonist, is currently under investigation and
demonstrated improved gastric emptying.19 Prucalopride, a selective 5-HT4 receptor agonist
without adverse cardiac effects, exerts an enterokinetic effect and is approved in the United
States for the treatment of chronic constipation.14 Prucalopride has been shown to exhibit a
gastrokinetic effect and improved symptoms in patients with idiopathic gastroparesis,
significantly improving symptoms of nausea/vomiting, fullness/satiety, and bloating/distention;
improved quality of life; and enhanced solid gastric emptying compared to placebo.14,21 Adverse
effects of prucalopride are diarrhea, headache and nausea, though most events were transient.21
Though 5-HT4 agonists were previously utilized to treat gastroparesis, currently no other 5-HT4
agonists have been FDA-approved.3
Buspirone and acotiamide are fundic relaxants being investigated for symptomatic
treatment in patients with gastroparesis.14 Buspirone is an anxiolytic 5-HT1A agonist that
enhances gastric accommodation through fundic relaxation and improves postprandial symptoms
in patients with gastroparesis independently from its anxiolytic effect.14 Acotiamide, a
cholinesterase inhibitor, exerts presynaptic muscarinic autoreceptor inhibitory activity,
enhancing both contractile and accommodation activities of the stomach and improving
dyspeptic symptoms but not epigastric pain or burning symptoms.14
Tricyclic antidepressants (TCAs), such as nortriptyline and amitriptyline, are
psychotropic agents that have been utilized for patients with idiopathic gastroparesis to treat
refractory symptoms of nausea, vomiting, and abdominal pain.1,6,8 Some TCAs delay gastric
emptying, but nortriptyline was indicated as the least likely TCA to affect gastric emptying since
it exhibits less anticholinergic side effects than other TCAs.1 A randomized, placebo-controlled
study demonstrated that nortriptyline did not result in improvement in overall symptoms in
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patients with idiopathic gastroparesis, which does not support the use of TCAs for the treatment
of idiopathic gastroparesis.1,6,11 Mirtazapine is an antidepressant with central adrenergic and
serotonergic activity.14 Mirtazapine may be helpful in patients with idiopathic gastroparesis
experiencing loss of appetite and weight loss as it was shown to improve nausea, vomiting and
loss of appetite in patients with gastroparesis.14
Patients with gastroparesis may experience pylorospasm due to excessive smooth muscle
tone, resulting in failure of the pylorus to relax and causing functional resistance to gastric
outflow.10 Botulinum toxin (BTX) is a neurotoxin that inhibits acetylcholine release from
synaptic vesicles at synaptic junctions, which decreases the release of excitatory transmitter
substances in muscles, promoting relaxation.3,8,10 BTX injected intrapylorically has been utilized
in patients with idiopathic gastroparesis experiencing pylorospasm to decrease pyloric resistance
and subsequently improve gastric emptying.3,10 It is more invasive due to the injection needing to
be administered endoscopically. BTX has shown mixed results in its effects on symptoms and
gastric emptying in patients across various studies.3,8,10,14 Its use remains controversial in the
treatment of idiopathic gastroparesis due to its utilization being considered an off-label indication
in treating patients with idiopathic gastroparesis and the lack of clinical evidence to support
widespread use in patients with idiopathic gastroparesis.3,8,10,14
Pain is an important symptom in patients with idiopathic gastroparesis that typically does
not improve with dietary adjustments or other medical interventions, which reduces a ie
quality of life.12,15,18 Abdominal pain in patients with idiopathic gastroparesis is poorly
understood and frequently difficult to treat, often driving patients toward opioids.5,14 However,
opioid medications should be avoided in patients with idiopathic gastroparesis. Suggested
medications to treat abdominal pain in patients with idiopathic gastroparesis are non-steroidal
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anti-inflammatory drugs (NSAIDs) that may help by improving gastric dysrhythmias.10 Other
options are antidepressant medications like selective serotonin reuptake inhibitors (SSRIs),
tricyclic antidepressants (TCAs), serotonin/norepinephrine reuptake inhibitors (SNRIs),
gabapentin, and pregabalin, which may help improve neuropathic pain associated with
gastroparesis.10,15 Haloperidol administered intravenously in the Emergency Department
decreased abdominal pain and nausea in severely ill patients with gastroparesis. 14
Opioid analgesics may acutely improve abdominal pain.6 However, they delay gastric
emptying, can cause symptoms of both nausea and vomiting, may actually upregulate abdominal
pain, and lead to dependence due to chronic usage.6 Therefore, treatment guidelines advise that
opioid analgesics not be used to manage abdominal pain in patients with idiopathic
gastroparesis.5,10 Figure 3 features data regarding the degree of gastric emptying delay in patients
prescribed opioids.5 Navas et al. report that about 25% of patients in their study had an active
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oxycodone was the most common opioid prescribed to the patients in their study.5 Others have
published that up to 42% of patients with gastroparesis have been prescribed opioids.5 Opiate
analgesic use correlates with increased severity of gastric emptying, worsens nausea and
vomiting, lowers quality of life, causes greater resource utilization, and carries an addictive
potential.5,15,16,22 Potent opioids (morphine, hydrocodone, oxycodone, methadone,
hydromorphone, buprenorphine, or fentanyl) are associated with larger effects than weaker
agents (tapentadol, tramadol, codeine, or propoxyphene).22 Furthermore, gastroparesis patients
taking opioids report greater severity of symptoms and experience more than double the
hospitalization rates when compared to those who do not take opioids.5
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Overall, healthcare providers are advised to not prescribe opioids to patients with
idiopathic gastroparesis.5 Providers are also advised to wean patients with idiopathic
gastroparesis off opioids and choose an alternative analgesic to treat the abdominal pain
associated with the motility disorder, specifically choosing alternative medications that do not
further delay gastric emptying nor directly cause nausea and vomiting.5 Pain improvement
should result in better symptom control, improved quality of life, restoration of productivity, and
reduced ED visits, hospitalizations, and associated healthcare costs.5,12
VI. Methods
Idiopathic Gastroparesis General Information
To compile background information regarding idiopathic gastroparesis, a PubMed search was
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articles published in the last 10 years. Articles selected broadly discussed the definition,
prevalence, and methods of diagnosing idiopathic gastroparesis. Other articles selected also
included the treatment and management of the chronic motility disorder.
Lifestyle Modifications for the Treatment of Idiopathic Gastroparesis
To compile information regarding the treatment of idiopathic gastroparesis utilizing lifestyle
modifications, including dietary adjustments and changes in eating habits, a PubMed search was
performed using the following terms and search filter applied for articles published in the last 10
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Articles chosen discussed lifestyle modifications, dietary recommendations, nutritional
deficiencies, and overall discussion of health and nutrition in patients with idiopathic
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gastroparesis.
Pharmacotherapy for the Treatment of Idiopathic Gastroparesis
To compile further information regarding pharmacotherapy utilized for treating the symptoms
and delayed gastric emptying associated with idiopathic gastroparesis, a PubMed search was
performed using the following terms and search filter applied for articles published in the last 10
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medications but also medications being used off-label for the treatment of symptoms and delayed
gastric emptying associated with idiopathic gastroparesis. Other articles chosen provided a
review of medications being investigated through clinical trials for potential use in the treatment
of idiopathic gastroparesis.
VII. Discussion
Idiopathic gastroparesis is a chronic gastric motility disorder that impacts patients' quality
of life and has limited FDA-approved pharmacotherapy options for the treatment of symptoms
and management of the complex disorder. It is concerning that patients are willing to take high
risks with medications in order to achieve symptom relief, but this is also understandable once
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impact on quality of life is observed. Patients with idiopathic

gastroparesis require a treatment plan to include dietary adjustments and potentially
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to prevent ED visits, hospitalizations, and accumulation of healthcare costs. In utilizing the least
invasive treatment options first, the research question investigated through this literature review
was: in adults with idiopathic gastroparesis, how does lifestyle modifications, including changing
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diet and eating habits, compared to pharmacotherapy affect the symptoms of nausea, vomiting,
early satiety, and poor appetite?
The evaluation of patients with idiopathic gastroparesis and the treatment plan for their
symptoms and delayed gastric emptying needs to be thorough. A 4-hour gastric emptying study
is the gold standard to establish the diagnosis of gastroparesis. However, a protocol to further
classify the delay as mild, moderate or severely delayed has not been agreed upon nor published.
A thorough history and physical examination should be performed to identify and minimize or
eliminate any factors that may be contributing to symptoms, including discontinuing medications
that provoke symptoms or delay gastric emptying, addressing hydration and nutritional
deficiencies, and treating any comorbidities. Laboratory studies are a vital component to evaluate
for and identify electrolyte and nutritional abnormalities and any other underlying conditions that
may be contributing to symptoms. If nutritional supplementation is required, high protein caloric
liquids are recommended, as liquids are often better tolerated than solids.
Patient education is crucial in helping patients understand their diagnosis, the importance
of following a gastroparesis diet, and understanding the purpose of prescribed pharmacotherapy.
Education empowers patients to take charge of their health and helps them make appropriate
lifestyle modifications to improve and potentially eliminate their symptoms. The provider should
perform education regarding a gastroparesis diet, to include the frequency and composition of
meals. Small frequent meals (4 to 6 meals daily) low in fiber and fats are recommended for
patients with the diagnosis of idiopathic gastroparesis to maintain nutrition. Additionally, liquidbased meals to maintain nutrition and adequate fluid intake to maintain hydration are
recommended during symptomatic flares. This may also help resolve associated complications
and prevent future complications associated with persistent symptoms. Based on the data
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available indicating that very few patients follow a gastroparesis diet, the challenges with
adherence need to be quickly identified and addressed. If possible, a registered dietitian should
be involved in the patient education regarding a gastroparesis diet, nutritional assessment, and
meal planning. If not possible, it is the responsibility of the provider to educate and aid the
patient in each of these areas and address any challenges as they arise.
If symptoms are still present after lifestyle and dietary modifications, pharmacotherapy
can be instituted and individualized to target specific symptoms, such as antiemetics, prokinetic
medications, analgesic medications, and antidepressants. However, opioid analgesics are not
recommended and should be completely avoided to treat pain in patients with idiopathic
gastroparesis because they delay gastric emptying and can directly cause the symptoms of nausea
and vomiting. Unfortunately, metoclopramide is the only medication FDA-approved in the
United States for the indication of treating gastroparesis. This highlights the need for more
medications to be investigated for the treatment of idiopathic gastroparesis and the need for these
medications to be approved specifically for the indication of idiopathic gastroparesis or
symptoms induced by the disorder.
Other medications are prescribed to treat specific symptoms or prescribed off-label for
treating idiopathic gastroparesis. Antiemetics, for example, are often prescribed and labeled for
the indication of pregnancy-induced or chemotherapy-induced nausea and vomiting but are
utilized off-label to treat nausea and vomiting associated with idiopathic gastroparesis. The
largest challenge with prescribing medications for off-label use is the ability to obtain
pharmaceutical insurance coverage for the cost of the medications. Thorough documentation
(including medication name, dosage, dates and duration of trials, and reason for failure) of
previous medication trials needs to occur with every patient encounter and the information
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utilized when performing medication prior authorizations for pharmaceutical insurance coverage.
If the insurance company will not pay for the medication, either the patient will need to pay outof-pocket for the medication or the healthcare provider needs to choose a formulary alternative (a
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symptoms, so shared decision-making is important when deciding which medications to
prescribe to target specific symptoms. Once started, each medication dose will need to be
adjusted or discontinued based on symptom response and associated side-effects. More severe
symptoms may need to be initially treated with both lifestyle modifications and
pharmacotherapy.
Based on the literature review, the treatment regimen for a patient with idiopathic
gastroparesis, including lifestyle modifications, dietary adjustments and pharmacotherapy, will
need to be formulated and adjusted on a case-by-case basis depending on presenting symptoms
and the severity of symptoms. Lifestyle modifications, including changing diet and eating habits
compared to pharmacotherapy affect the symptoms of nausea, vomiting, early satiety, and poor
appetite unpredictably. This information is crucial to communicate to the patient during the
patient education component of each visit, reminding patients that the goal of treatment is to
control symptoms and improve their quality of life through lifestyle modifications,
pharmacotherapy, or both. Since the response to dietary changes and pharmacotherapy is
unpredictable, consistent follow-up is required to evaluate for symptom improvement, monitor
for medication side-effec , a d a e
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VIII. Conclusion
Idiopathic gastroparesis is a chronic gastric motility disorder of unknown cause that
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patients with idiopathic gastroparesis is to control symptoms, not cure the disorder, which is an
important education distinction to provide to the patient upon establishing the diagnosis of
idiopathic gastroparesis. The delay in gastric emptying may predict negative health outcomes
and exacerbate comorbid conditions in patients with symptomatic gastroparesis, increasing the
possibility of a necessary hospitalization for a higher level of treatment and management.5 The
increase in hospitalizations of gastroparesis patients and increase in associated healthcare costs
over the last 15 years emphasizes the importance and necessity of outpatient clinical treatment
and management plans of this chronic motility disorder.5
Lifestyle modifications and dietary adjustments are the first step in treating patients with
idiopathic gastroparesis with the potential for pharmacotherapy to also be instituted to reduce or
potentially eliminate symptoms. Patients should eat four to six small meals daily that are both
low in fat and fiber to maintain nutrition. During symptomatic flares, patients should consume
liquid-based meals to maintain nutrition and drink fluids as tolerated to maintain hydration.
Metoclopramide is the only FDA-approved mediation for the treatment of gastroparesis, which
means pharmacotherapy options are limited at this time. There are many emerging medications
currently in clinical trials for the treatment of idiopathic gastroparesis, associated symptoms,
and/or delay in gastric emptying. Pharmacotherapy is available to treat individual symptoms,
such as antiemetics for the treatment of nausea and vomiting; however, the majority of other
medications (those indicated for the treatment of other chronic conditions) are prescribed as an

Idiopathic Gastroparesis: Lifestyle Modifications Versus Pharmacotherapy 29
off-label use of the medication for the treatment of symptoms and delayed gastric emptying
associated with idiopathic gastroparesis.
Utilizing pharmacotherapy to treat symptoms and delayed gastric emptying associated
with idiopathic gastroparesis can be both complicated and frustrating for patients and healthcare
providers. The challenge in using medications for off- abe i dica i

i ha
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pharmaceutical insurance plans may not cover the cost of the medications, since the diagnosis of
idiopathic gastroparesis is not listed as an FDA-approved indication. When pharmaceutical
insurance companies do not pay for the medication, either the patient has to pay out-of-pocket
for the entire cost of the medication or an alternative medication will need to be prescribed.
Further research needs to evaluate and approve medications for the indication of treating
symptoms and/or delayed gastric emptying associated with idiopathic gastroparesis.
Furthermore, side-effects associated with medications also limit the use of pharmacotherapy in
the treatment of idiopathic gastroparesis. Mediation is utilized to treat specific symptoms or the
specific cause of symptoms; however, patient tolerance, symptom response, and side-effects
must be monitored closely and adjustments to doses or changes in medications made as needed.
Since associate providers, such as physician assistants, have been shown to reduce costs
and readmission rates for other chronic disease models as well as improve outcomes in the
primary care setting, certified physician assistants have the opportunity to contribute to reduced
costs and improved outcomes for patients with idiopathic gastroparesis.5 The recommendations
regarding symptomatic treatment and management of patients with idiopathic gastroparesis will
influence the medical practice of not only certified physician assistants (PAs) but also physicians
and nurse practitioners (NPs) treating these patients. With data demonstrating that very few
patients follow a gastroparesis diet, healthcare providers have a unique opportunity to educate
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patients with idiopathic gastroparesis regarding lifestyle modifications and dietary
recommendations. Physicians, PAs, and NPs have the opportunity to troubleshoot appointment
scheduling and insurance coverage on a case-by-case basis in order to facilitate appointments not
only with themselves but also with a registered dietitian, improve patients' quality of life,
hopefully minimize or eliminate the need for ED visits and hospitalizations, and reduce
healthcare costs not only for the patient but also for our healthcare systems as a whole. Since
most patients are not following a gastroparesis diet, patient education by healthcare providers
regarding diet is a necessary component of management and treatment of patients with idiopathic
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consultation with a registered dietitian. Another question that arose during this literature review
was whether following a gastroparesis diet customized to the patient's nutritional requirements
and individualized to their lifestyle may relieve symptoms more than pharmacotherapy in
patients with idiopathic gastroparesis. Further research should specifically evaluate the effect of
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review performed for this paper, customization is key in the treatment and management of
patients with idiopathic gastroparesis.
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DM indicates diabetes mellitus; GP, gastroparesis; GLP, glucagon-like peptide; TD, tardive
dyskinesia.

Idiopathic Gastroparesis: Lifestyle Modifications Versus Pharmacotherapy 37
Table 2: Nutritional Analysis of Aggravating and Tolerated Foods13

Idiopathic Gastroparesis: Lifestyle Modifications Versus Pharmacotherapy 38
Table 3: Food Qualities of Aggravating and Tolerated Foods13

Idiopathic Gastroparesis: Lifestyle Modifications Versus Pharmacotherapy 39
Table 4: Treatments Tried for Gastroparesis Symptoms (n=284)5

Idiopathic Gastroparesis: Lifestyle Modifications Versus Pharmacotherapy 40
Table 5: Novel Drug Effects19

Table 6: Mechanisms of Action of Novel Drugs19

Idiopathic Gastroparesis: Lifestyle Modifications Versus Pharmacotherapy 41
Figure 3: Degree of Gastric Emptying Delay in Patients Prescribed Opioids 5

